Veil Fluid Makeup Sable
- Manufacturer
- Kingdom Animalia, LLC. DBA Hourglass Cosmetics
- Effective date
- 2020-12-08
- Label type
- HUMAN OTC DRUG LABEL
- Version
- 19
- Source
- legacy-cache
- Hydrated at
- 2026-08-01 23:03:31
Label at a glance#
Contacts and useful links#
Label contents#
Full prescribing information#
OTC - ACTIVE INGREDIENT SECTION
Active Ingredients Purpose
Octinoxate 7.5% Sunscreen
Octisalate 4.0% Sunscreen
Oxybenzone 3.0% Sunscreen
OTC - PURPOSE SECTION
Enter section text here
INDICATIONS & USAGE SECTION
- helps prevent sunburn
- if used as directed with other sun protection measures (see Directions), decrease the risk of skin cancer and early skin aging cause by the sun.
WARNINGS SECTION
For external use only.
OTC - DO NOT USE SECTION
Do not use on damage or broken skin.
OTC - WHEN USING SECTION
When using this product keep out of eyes. If contact occurs, rinse thoroughly with water.
OTC - STOP USE SECTION
Stop Use and ask a doctor if irritation or rash develops.
OTC - KEEP OUT OF REACH OF CHILDREN SECTION
Keep out of reach of children. If product is swallowed, get medical help or contact a Poison Control Center right away.
INSTRUCTIONS FOR USE SECTION
Directions
- SHAKE WELL, and apply to moisturized or primed skin with fingertips or Hourglass Foundation Brush.
- Sun Protection Measures. Spending time in the sun increases your risk of skin cancer and early skin aging. To decrease this risk, regularly use a sunscreen with a broad spectrum SPF of 15 or higher and other sun protection measures including:
- limit time in the sun, especially from 10 a.m.- 2 p.m.
- wear long-sleeve shirts, pants, hats and sunglasses.
- Children under 6 months: Ask a doctor.
INACTIVE INGREDIENT SECTION
Inactive Ingredients CETEARYL ETHYLHEXANOATE, CETYL PEG/PPG 10/1 DIMETHICONE, CYCLOPENTASILOXANE, DIMETHICONE, ETHYLHEXYLGLYCERIN, GLYCERIN, GLYCERYL BEHENATE, GLYCERYL DIBEHENATE, HDI/TRIMETHYLOL HEXYLLACTONE CROSS-POLYMER, HEXYL LAURATE, HYDROLYZED WHEAT PROTEIN, HYDOXYPROPYL CYCLODEXTRIN, ISODODECANE, ISOEICOSANE, MACROCYSTIC PYRIFERA EXTRACT, MAGNESIUM SULFATE, PALMITOYL TRIPEPTIDE-38, PENTAERYTHRITYL TETRAISOSTEARATE, PHENOXYETHANOL, PHENYL TRIMETHICONE, POLYGLYCERYL-4 ISOSTEARATE, POTASSIUM SORBATE, PROPYLENE CARBONATE, PVP, QUATERNIUM-90 BENTONITE, SILICA, SODIUM BENZOATE, TOCOPHERYL ACETATE, TRIBEHENIN, TRIETHOXYLCAPRYLYLSILANE, WATER. MAY CONTAIN (+/-): IRON OXIDES (CI 77491), IRON OXIDES (CI 77492), IRON OXIDES (CI 77499), TITANIUM DIOXIDE (CI 77891).
OTHER SAFETY INFORMATION
Other Information
Protect this product from excessive heat and direct sun.
OTC - QUESTIONS SECTION
Questions or comments?
CALL TOLL FREE 855-201-4529
HOW SUPPLIED SECTION
DIST. BY KINGDOM ANIMALIA, LLC. VENICE, CA 90291 USA
HOURGLASS COSMETICS, UK LTD, LONDON WC1D 3JA
MADE IN USA PRODUCT NOT TESTED ON ANIMALS
PACKAGE LABEL.PRINCIPAL DISPLAY PANEL
DailyMed Socrata Ingredients#
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| OCTINOXATE | ACTIVE INGREDIENT | 4Y5P7MUD51 | 9 | |
| OCTISALATE | ACTIVE INGREDIENT | 4X49Y0596W | 9 | |
| OXYBENZONE | ACTIVE INGREDIENT | 95OOS7VE0Y | 9 | |
| OCTINOXATE | ACTIVE MOIETY | 4Y5P7MUD51 | 9 | |
| OCTISALATE | ACTIVE MOIETY | 4X49Y0596W | 9 | |
| OXYBENZONE | ACTIVE MOIETY | 95OOS7VE0Y | 9 | |
| .ALPHA.-TOCOPHEROL ACETATE | INACTIVE INGREDIENT | 9E8X80D2L0 | 9 | |
| BIOTIN | INACTIVE INGREDIENT | 6SO6U10H04 | 9 | |
| CETEARYL ETHYLHEXANOATE | INACTIVE INGREDIENT | 9M64UO4C25 | 9 | |
| CETYL PEG/PPG-10/1 DIMETHICONE (HLB 5) | INACTIVE INGREDIENT | 035JKJ76MT | 9 | |
| CYCLOMETHICONE 5 | INACTIVE INGREDIENT | 0THT5PCI0R | 9 | |
| DIMETHICONE | INACTIVE INGREDIENT | 92RU3N3Y1O | 9 | |
| EDETATE TRISODIUM | INACTIVE INGREDIENT | 420IP921MB | 9 | |
| ETHYLHEXYLGLYCERIN | INACTIVE INGREDIENT | 147D247K3P | 9 | |
| FERRIC OXIDE RED | INACTIVE INGREDIENT | 1K09F3G675 | 9 | |
| FERRIC OXIDE YELLOW | INACTIVE INGREDIENT | EX438O2MRT | 9 | |
| FERROSOFERRIC OXIDE | INACTIVE INGREDIENT | XM0M87F357 | 9 | |
| GLYCERIN | INACTIVE INGREDIENT | PDC6A3C0OX | 9 | |
| GLYCERYL DIBEHENATE | INACTIVE INGREDIENT | R8WTH25YS2 | 9 | |
| HEXYL LAURATE | INACTIVE INGREDIENT | 4CG9F9W01Q | 9 | |
| HYDROLYZED WHEAT PROTEIN (ENZYMATIC, 3000 MW) | INACTIVE INGREDIENT | J2S07SB0YL | 9 | |
| ISODODECANE | INACTIVE INGREDIENT | A8289P68Y2 | 9 | |
| ISOEICOSANE | INACTIVE INGREDIENT | AR294KAG3T | 9 | |
| MAGNESIUM SULFATE | INACTIVE INGREDIENT | DE08037SAB | 9 | |
| PALMITOYL TRIPEPTIDE-5 | INACTIVE INGREDIENT | 2A3916MQHO | 9 | |
| PENTAERYTHRITYL TETRAISOSTEARATE | INACTIVE INGREDIENT | 9D7IK5483F | 9 | |
| PHENOXYETHANOL | INACTIVE INGREDIENT | HIE492ZZ3T | 9 | |
| PHENYL TRIMETHICONE | INACTIVE INGREDIENT | DR0K5NOJ4R | 9 | |
| POLYGLYCERYL-4 ISOSTEARATE | INACTIVE INGREDIENT | 820DPX33S7 | 9 | |
| POTASSIUM SORBATE | INACTIVE INGREDIENT | 1VPU26JZZ4 | 9 | |
| PROPYLENE CARBONATE | INACTIVE INGREDIENT | 8D08K3S51E | 9 | |
| QUATERNIUM-91 | INACTIVE INGREDIENT | 00J8H295NB | 9 | |
| SILICON DIOXIDE | INACTIVE INGREDIENT | ETJ7Z6XBU4 | 9 | |
| SODIUM BENZOATE | INACTIVE INGREDIENT | OJ245FE5EU | 9 | |
| TITANIUM DIOXIDE | INACTIVE INGREDIENT | 15FIX9V2JP | 9 | |
| TRIBEHENIN | INACTIVE INGREDIENT | 8OC9U7TQZ0 | 9 | |
| WATER | INACTIVE INGREDIENT | 059QF0KO0R | 9 |
Products#
Every source-derived product name is available through these pages.
- Veil Fluid Makeup Sable SPF 15
- Octinoxate, Octisalate, Oxybenzone
- OCTINOXATE
- OCTISALATE
- OXYBENZONE
- WATER
- GLYCERIN
- MAGNESIUM SULFATE, UNSPECIFIED
- PALMITOYL TRIPEPTIDE-5
- HYDROLYZED WHEAT PROTEIN (ENZYMATIC, 3000 MW)
- PHENOXYETHANOL
- POTASSIUM SORBATE
- BIOTIN
- EDETATE TRISODIUM
- SODIUM BENZOATE
- POLYGLYCERYL-4 ISOSTEARATE
- CETYL PEG/PPG-10/1 DIMETHICONE (HLB 5)
- HEXYL LAURATE
- .ALPHA.-TOCOPHEROL ACETATE
- GLYCERYL DIBEHENATE
- TRIBEHENIN
- ETHYLHEXYLGLYCERIN
- ISODODECANE
- QUATERNIUM-91
- PROPYLENE CARBONATE
- CYCLOMETHICONE 5
- DIMETHICONE
- CETEARYL ETHYLHEXANOATE
- PHENYL TRIMETHICONE
- SILICON DIOXIDE
- PENTAERYTHRITYL TETRAISOSTEARATE
- ISOEICOSANE
- TITANIUM DIOXIDE
- FERRIC OXIDE YELLOW
- FERRIC OXIDE RED
- FERROSOFERRIC OXIDE
NDC Codes#
| Product NDC | Package NDC |
|---|---|
| 42627-209 | 42627-209-01, 42627-209-02 |
Ingredients#
Every source-derived ingredient row is available through these pages.
Source Document#
Inactive ingredient matches#
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| FERROSOFERRIC OXIDE | FERROSOFERRIC OXIDE | XM0M87F357 | TABLET / ORAL | 2 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | CAPSULE, LIQUID FILLED / ORAL | 106 mg | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | TABLET, COATED / ORAL | 49 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SOLUTION / TOPICAL | 1971 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | AEROSOL / TOPICAL | 3 %w/w | ||
| FERRIC OXIDE RED | FERRIC OXIDE RED | 1K09F3G675 | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 3.6 mg | ||
| SODIUM BENZOATE | SODIUM BENZOATE | OJ245FE5EU | INJECTION, EMULSION / INTRAVENOUS | 0.1 %w/v | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SOLUTION / ORAL | 32400 mg | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | CAPSULE, DELAYED RELEASE PELLETS / ORAL | 24 mg | ||
| POTASSIUM SORBATE | POTASSIUM SORBATE | 1VPU26JZZ4 | SOLUTION / RECTAL | 6.67 %w/v | ||
| SODIUM BENZOATE | SODIUM BENZOATE | OJ245FE5EU | TABLET, FILM COATED / ORAL | 1 mg | ||
| FERRIC OXIDE YELLOW | FERRIC OXIDE YELLOW | EX438O2MRT | TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE / ORAL | 2 mg | ||
| SODIUM BENZOATE | SODIUM BENZOATE | OJ245FE5EU | GEL / RECTAL | 406 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | PASTE / DENTAL | 34 %w/w | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | INJECTION / INTRADERMAL | 1.6 %w/v | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | FILM, EXTENDED RELEASE / TRANSDERMAL | NA | ||
| FERRIC OXIDE RED | FERRIC OXIDE RED | 1K09F3G675 | CAPSULE / ORAL | 5 mg | ||
| POTASSIUM SORBATE | POTASSIUM SORBATE | 1VPU26JZZ4 | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 0.2 mg | ||
| POTASSIUM SORBATE | POTASSIUM SORBATE | 1VPU26JZZ4 | GRANULE, FOR SUSPENSION / ORAL | 80 mg | ||
| .ALPHA.-TOCOPHEROL ACETATE | .ALPHA.-TOCOPHEROL ACETATE | 9E8X80D2L0 | TABLET / ORAL | 0.5 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | SOLUTION / ORAL | 336 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SOLUTION / DENTAL | 15 %w/v | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | FILM, SOLUBLE / ORAL | 2 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | CAPSULE, COATED / ORAL | 14.21 mg | ||
| SODIUM BENZOATE | SODIUM BENZOATE | OJ245FE5EU | SUSPENSION, EXTENDED RELEASE / ORAL | 24 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | GRANULE, FOR SOLUTION / ORAL | 1.8 mg/120ml | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | INJECTION / INTRAVENOUS | 33750 mg | ||
| CYCLOMETHICONE 5 | CYCLOMETHICONE 5 | 0THT5PCI0R | AEROSOL, FOAM / TOPICAL | 144 mg | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE / ORAL | 42 mg | ||
| EDETATE TRISODIUM | EDETATE TRISODIUM | 420IP921MB | CREAM / TOPICAL | NA | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | POWDER / RESPIRATORY (INHALATION) | NA | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | PELLET / ORAL | 34 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | TABLET, FILM COATED / ORAL | 1.55 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | TABLET, COATED / ORAL | 1 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | INJECTION, EMULSION / INTRAVENOUS | 24100 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | POWDER / ORAL | 602 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | POWDER, FOR SOLUTION / ORAL | 280 mg | ||
| GLYCERYL DIBEHENATE | GLYCERYL DIBEHENATE | R8WTH25YS2 | POWDER, FOR SOLUTION / ORAL | 8 mg | ||
| SODIUM BENZOATE | SODIUM BENZOATE | OJ245FE5EU | INJECTION / INTRAMUSCULAR | 864 mg | ||
| FERRIC OXIDE YELLOW | FERRIC OXIDE YELLOW | EX438O2MRT | FILM / BUCCAL | 0.27 mg | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | DROPS / ORAL | NA | ||
| SODIUM BENZOATE | SODIUM BENZOATE | OJ245FE5EU | GEL / TOPICAL | 5 mg | ||
| SODIUM BENZOATE | SODIUM BENZOATE | OJ245FE5EU | CAPSULE / ORAL | 8.5 mg | ||
| FERRIC OXIDE RED | FERRIC OXIDE RED | 1K09F3G675 | POWDER, FOR SUSPENSION / ORAL | 1 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | EMULSION / INTRAVENOUS | 2.2 %w/v | ||
| SODIUM BENZOATE | SODIUM BENZOATE | OJ245FE5EU | POWDER, FOR SUSPENSION / ORAL | 160 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SYSTEM / TOPICAL | 18144 mg | ||
| SODIUM BENZOATE | SODIUM BENZOATE | OJ245FE5EU | ENEMA / RECTAL | 60 mg | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | TABLET, ORALLY DISINTEGRATING / ORAL | 6 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | GRANULE / ORAL | 5000 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | FILM, SOLUBLE / ORAL | 2 mg | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | POWDER / RESPIRATORY (INHALATION) | 2 mg | ||
| POTASSIUM SORBATE | POTASSIUM SORBATE | 1VPU26JZZ4 | SOLUTION/ DROPS / OPHTHALMIC | 0.47 %w/v | ||
| POTASSIUM SORBATE | POTASSIUM SORBATE | 1VPU26JZZ4 | SOLUTION / ORAL | 1000 mg/15ml | ||
| FERRIC OXIDE YELLOW | FERRIC OXIDE YELLOW | EX438O2MRT | CAPSULE, EXTENDED RELEASE / ORAL | 7 mg | ||
| FERROSOFERRIC OXIDE | FERROSOFERRIC OXIDE | XM0M87F357 | CAPSULE, EXTENDED RELEASE / ORAL | 1.49 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE / ORAL | 69 mg | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | FILM, SOLUBLE / BUCCAL | 11 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | ELIXIR / ORAL | 5621 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET, DELAYED RELEASE PARTICLES / ORAL | 170 mg |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| e1696e00-3ec3-4e4c-8edd-c762ff15717b | 28eb482e-ea98-49c1-b88c-5cc28fba7c58 | 2020-12-08 | Warnings | e1696e00-3ec3-4e4c-8edd-c762ff15717b 28eb482e-ea98-49c1-b88c-5cc28fba7c58 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.
